Addus HomeCare
Provides in-home personal care, hospice, and home health services.
Something off on this page? Send us feedback.
Profile
Provides in-home personal care, hospice, and home health services, earning revenue from government programs, managed care organizations, insurers, and private-pay clients. Personal care generates most revenue, while acquisitions expand local density and clinical reach; the model depends on caregiver availability and regulated reimbursement.
Provides in-home personal care, hospice, and home health services across U.S. state markets. Personal care, the anchor segment, helps older adults and people with chronic illnesses or disabilities with activities of daily living. Hospice delivers physical, emotional, and spiritual support for terminally ill patients and their families, while home health supplies skilled nursing and rehabilitation after illness or hospitalization.
Combines organic expansion with acquisitions that deepen local density, add state markets, and extend clinical services; selected states offer all three levels of care. Revenue comes from federal, state, and local programs, managed care organizations, commercial insurers, and private-pay clients, and many consumers qualify for both Medicare and Medicaid.
Operations depend on caregiver recruitment and retention, reimbursement rates, licensing and program rules, and integration of acquired agencies.
Company facts
Key statistics
Year to date +8.4% · Average volume (30d) 211.1K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 5, 2026 | RBC Capital | Reiterate | Outperform | $139 | $134 |
| Jul 8, 2026 | Barclays | Reiterate | Underweight | $92 | $96 |
| May 15, 2026 | Barclays | Reiterate | Underweight | $112 | $92 |
| Feb 25, 2026 | RBC Capital | Target | $141 | $139 | |
| Feb 24, 2026 | Barclays | Reiterate | Underweight | $117 | $112 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026Q2 FY26 | $1.70 | $1.73 | +1.8% | $376.2M | $377.4M | +0.3% | −2.68% |
| May 4, 2026Q1 FY26 | $1.52 | $1.62 | +6.6% | $366.4M | $363.5M | −0.8% | −1.68% |
| Feb 23, 2026Q4 FY25 | $1.71 | $1.77 | +3.5% | $372.9M | $372.1M | −0.2% | −10.57% |
| Nov 3, 2025Q3 FY25 | $1.53 | $1.56 | +2.0% | $372.9M | $362.3M | −2.8% | −5.69% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $337.7M | $349.4M | $362.3M | $373.1M | $363.6M | $377.4M | |
| Gross profit | $107.7M | $113.9M | $116.7M | $123.6M | $115.9M | $121.6M | |
| Operating income | $30.5M | $32.9M | $32.9M | $42.3M | $34.1M | $38.9M | |
| Net income | $21.2M | $22.1M | $22.8M | $29.8M | $25.1M | $27.6M | |
| Diluted EPS | $1.16 | $1.20 | $1.24 | $1.61 | $1.36 | $1.49 | |
| Gross margin | 31.9% | 32.6% | 32.2% | 33.1% | 31.9% | 32.2% | |
| Operating margin | 9.0% | 9.4% | 9.1% | 11.3% | 9.4% | 10.3% |
Fiscal years (4-quarter sums)FY21 $864.5M · FY22 $951.1M · FY23 $1.06B · FY24 $1.15B · FY25 $1.42B
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $99.6M · Total debt $108.8M · Total assets $1.46B · Shareholders' equity $1.15B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 18.66M · Float 18.13M · 97.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.43M | 18.35% | 13F | Aug 7, 2026 |
| Capital Research Global Investors | 1.39M | 7.45% | 13F | Aug 12, 2026 |
| Dimensional Fund Advisors LP | 835.2K | 4.47% | 13F | Aug 11, 2026 |
| Vanguard Capital Management LLC | 789.3K | 4.23% | 13F | Aug 13, 2026 |
| State Street Corp | 777.8K | 4.17% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 22, 2026 | Heather Brianne Dixon | officer: President and Chief Operating | −288 | $93.77 |
| May 21, 2026 | Esteban Lopez | director | −250 | $93.00 |
| May 19, 2026 | Esteban Lopez | director | −250 | $93.00 |
| Apr 21, 2026 | Cliff Donald Blessing | officer: EVP, Chief Development Officer | −178 | $93.61 |
| Mar 2, 2026 | Monica Raines | officer: EVP, CCO and Quality Officer | −224 | $102.15 |
Peers
- BrightSpring Health Services
Broad HCBS platform with personal care and clinical overlap
- Aveanna Healthcare
Medicaid-heavy private-duty and home-health peer
- The Pennant Group
Regional home health and hospice operator with home care exposure
- UnitedHealth Group
Optum adds large-scale home health and hospice pressure
- Chemed
VITAS makes hospice the direct overlap
- Humana
CenterWell creates payer-owned home-health overlap
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Addus HomeCare | $115.55 | +0.02% | $2.16B | 20.3 | 16.1 | 1.5 | +8.0% |
| BrightSpring Health Services | $60.31 | +2.01% | $11.60B | 44.1 | 28.9 | 0.8 | +23.0% |
| Aveanna Healthcare | $13.67 | +2.70% | $2.90B | 10.5 | 16.2 | 1.1 | +13.7% |
| The Pennant Group | $37.08 | +0.05% | $1.29B | 41.2 | 25.6 | 1.2 | +35.8% |
| UnitedHealth Group | $392.50 | −0.12% | $356.86B | 25.3 | 18.4 | 0.8 | +0.4% |
| Chemed | $523.38 | +0.06% | $6.84B | 26.3 | 20.2 | 2.6 | +8.8% |
| Humana | $386.23 | +0.16% | $46.30B | 36.5 | 31.2 | 0.3 | +26.2% |
| Median | 31.4 | 22.9 | 1.0 | +18.4% |